Showing results (1311-1320 of 5,989) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|January 24, 2015
Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic conceptsVerena Paulitschke, Walter Berger, Philipp Paulitschke, et al.
Molecular Cancer Therapeutics|February 4, 2015
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatmentsFrank Loganzo, Xingzhi Tan, Matthew Sung, et al.
Molecular Cancer Therapeutics|February 4, 2015
New Blocking Antibodies against Novel AGR2-C4.4A Pathway Reduce Growth and Metastasis of Pancreatic Tumors and Increase Survival in MiceThiruvengadam Arumugam, Defeng Deng, Laura Bover, et al.
Molecular Cancer Therapeutics|July 2, 2014
Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapyAna Custodio, Juan Moreno-Rubio, Jorge Aparicio, et al.
Molecular Cancer Therapeutics|July 2, 2014
Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib)Jessica J Huck, Mengkun Zhang, Jerome Mettetal, et al.
Molecular Cancer Therapeutics|July 24, 2012
Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cellsAamir Ahmad, Sanila H Sarkar, Bassam Bitar, et al.
Molecular Cancer Therapeutics|August 21, 2012
Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivoRomain Coriat, Carole Nicco, Christiane Chéreau, et al.
Molecular Cancer Therapeutics|June 23, 2012
Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trialsRodrigo Dienstmann, Danila Serpico, Jordi Rodon, et al.
Molecular Cancer Therapeutics|July 5, 2012
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinibOndrej Kalous, Dylan Conklin, Amrita J Desai, et al.
Molecular Cancer Therapeutics|August 15, 2012
Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agentsSagar Agarwal, Rajendar K Mittapalli, David M Zellmer, et al.
Pageof 599